Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the adequacy of the availability and supply of ADHD medications.

We are aware of supply issues affecting one medication to treat attention deficit hyperactivity disorder (ADHD), methylphenidate prolonged-release. Other prolonged-release preparations remain available as well as other ADHD medication. Communications were issued to the National Health Service including all general practitioners and community pharmacists in May 2022, advising on available alternatives and how to manage affected patients during this time.